<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1494">
  <stage>Registered</stage>
  <submitdate>28/07/2006</submitdate>
  <approvaldate>5/09/2006</approvaldate>
  <actrnumber>ACTRN12606000388516</actrnumber>
  <trial_identification>
    <studytitle>A trial to assess the safety of nebulised heparin for acute lung injury</studytitle>
    <scientifictitle>A trial to assess the safety of nebulised heparin for acute lung injury</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acute lung injury</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Nebulised Heparin 25,000 U bd in normal saline. Given 12 hourly for 2 days.</interventions>
    <comparator>Control: normal saline. Given 12 hourly for 2 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety</outcome>
      <timepoint>All measured 1 hour after the nebulised drug is given.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Bleeding</outcome>
      <timepoint>All measured 1 hour after the nebulised drug is given.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Activated partial thromboplastin time</outcome>
      <timepoint>All measured 1 hour after the nebulised drug is given.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Alveolar dead space</outcome>
      <timepoint>Measured one hour after each episode of the nebulised drug.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Acute lung injurymechanical ventilation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Systemic heparin administrationPulmonary haemorrhage.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>30/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>St Vincents Health Melboune</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Intensive care foundation</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess whether nebulised heparin limits the extent of lung injury in patients with, or at risk of the acute respiratory distress syndrome.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Health Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/07/2006</ethicapprovaldate>
      <hrec>088/060</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St Vincents Health
55 Victoria Pde
Fitzroy VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884487</fax>
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barry Dixon</name>
      <address>St Vincents Health
55 Victoria Pde
Fitzroy VIC 3065</address>
      <phone>+61 3 92884488</phone>
      <fax>+61 3 92884487</fax>
      <email>barry.dixon@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>